{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colo-rectal+Cancer", "query": { "condition": "Colo-rectal Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2487, "total_pages": 249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colo-rectal+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:27:02.955Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00413322", "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413322" }, { "nct_id": "NCT05839951", "title": "An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer (mCRC)" ], "interventions": [ { "name": "Regorafenib (BAY73-4506, Stivarga®)", "type": "DRUG" }, { "name": "TAS-102 (trifluridine and tipiracil, Lonsurf®)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 818, "start_date": "2023-04-24", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05839951" }, { "nct_id": "NCT04952753", "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NIS793", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 204, "start_date": "2021-11-15", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 7, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952753" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Colorectal Cancer", "Cervical Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2013-12-19", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975831" }, { "nct_id": "NCT05246839", "title": "Informed Choice - Compass", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Brief Video", "type": "BEHAVIORAL" }, { "name": "Brief Video Plus", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "45 Years to 70 Years" }, "enrollment_count": 1823, "start_date": "2022-04-28", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Los Angeles, California • Port Hueneme, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Port Hueneme", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05246839" }, { "nct_id": "NCT01351103", "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "BRAF Mutant Colorectal Cancer", "Melanoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Cancer", "Cervical Squamous Cell Cancer", "Esophageal Squamous Cell Cancer", "Lung Squamous Cell Cancer" ], "interventions": [ { "name": "LGK974", "type": "DRUG" }, { "name": "PDR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2011-12-01", "completion_date": "2024-06-17", "has_results": false, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351103" }, { "nct_id": "NCT00352131", "title": "Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "HuC242-DM4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-02", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-03-17", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 2, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352131" }, { "nct_id": "NCT06818812", "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB186748", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-03-27", "completion_date": "2027-03-27", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 9, "location_summary": "Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06818812" }, { "nct_id": "NCT07219745", "title": "Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer", "Low Anterior Resection Syndrome" ], "interventions": [ { "name": "Peristeen Plus Irrigation kit", "type": "DEVICE" }, { "name": "LARS mobile application", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-11", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-05-21T22:27:02.955Z", "location_count": 1, "location_summary": "Weston, Florida", "locations": [ { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219745" } ] }